# ๐ŸŽฏ Renal Cell Carcinoma ### โšก Emergency Recognition Protocol 1 **Metastatic Disease Signs:** Bone pain, hemoptysis, neurologic changes, hypercalcemia 2 **Tumor Thrombus:** Lower extremity edema, varicocele, new heart murmur 3 **Hemorrhage Risk:** Large masses \>7cm, central location, prior intervention 4 **Urgent Referral:** Constitutional symptoms, rapidly growing mass, suspicious imaging ### ๐Ÿ“Š Epidemiology & Risk Factors - **Incidence Trends:** 1% per year increase 2015-2019 - **Mortality Improvement:** 2% per year decline 2016-2020 - **Early Detection:** 37-61% diagnosed incidentally on imaging - **Stage Distribution:** 70% present with stage I disease - **Most Common Cancer:** 6th in men, 9th in women - **Global Burden:** ~434,840 incident cases annually worldwide ### ๐Ÿงฌ Pathological Classification - **Clear Cell RCC:** 75-80% of cases, VHL gene inactivation - **Papillary RCC:** Type I and II variants, intermediate prognosis - **Chromophobe RCC:** Best prognosis, lowest metastatic risk - **Molecular Features:** VHL alterations drive metabolic reprogramming - **Histologic Impact:** Influences treatment selection and prognosis - **Grading Systems:** Fuhrman/ISUP grades correlate with outcomes ### ๐ŸŽฏ Size-Based Metastatic Risk Stratification #### T1a (โ‰ค4cm) 5.4% Overall progression rate at 35 months median follow-up #### T1b (4.1-7.0cm) 4-13% Varies by histologic subtype #### T2a (7.1-10cm) 15-20% Substantial increase in risk #### Histologic Risk Considerations: **Clear Cell:** Highest metastatic potential **Papillary:** Intermediate, size-dependent **Chromophobe:** Lowest risk, supports observation ### ๐Ÿงฎ RCC Metastatic Risk Calculator Tumor Size (cm): 3.0 cm Histologic Subtype: Estimated Metastatic Risk 6-8% Active surveillance appropriate for selected patients ### ๐Ÿ”ฌ Active Surveillance - **Growth Rate:** Median 2.8mm/year for T1a lesions - **Progression Risk:** 1-2% develop metastases during surveillance - **Optimal Candidates:** Elderly, comorbid, small tumors - **Protocol:** CT/MRI at 3-6 months, then annually - **Delayed Treatment:** No adverse oncologic outcomes - **Quality of Life:** Preserves function, avoids treatment toxicity ### โ„๏ธ Percutaneous Cryoablation - **Technical Success:** 95-96% for tumors โ‰ค4cm - **Optimal Size:** โ‰ค3cm lesions achieve \>95% success - **Local Control:** 95% at intermediate-term follow-up - **Renal Function:** Superior preservation vs partial nephrectomy - **5-Year RFS:** 85-90% for T1a lesions - **10-Year DSS:** 94% in prospective studies ### ๐Ÿ’Š Advanced RCC: Immunotherapy Revolution 1 **First-Line Standard:** Pembrolizumab + Axitinib (KEYNOTE-426) 2 **Alternative Combinations:** Nivolumab + Cabozantinib, Lenvatinib + Pembrolizumab 3 **Risk Stratification:** IMDC criteria guide treatment selection 4 **Sustained Benefit:** 5-year follow-up confirms durable responses ### โ„๏ธ Cryoablation Patient Selection #### โœ… Ideal Candidates - T1a masses โ‰ค3cm - Significant comorbidities - Solitary kidney - Hereditary syndromes - Patient preference #### โš ๏ธ Relative Contraindications - Tumors \>4cm - Central location - Collecting system proximity - Young healthy patients - Desire for definitive pathology #### Expected Outcomes by Size โ‰ค3cm: \>95% success 3-4cm: 90-95% success \>4cm: 85-90% success ### ๐Ÿ’Š Pembrolizumab + Axitinib - **KEYNOTE-426:** Superior efficacy vs sunitinib - **5-Year Follow-up:** Sustained benefit confirmed - **Response Rate:** 60.2% vs 39.6% with sunitinib - **Median OS:** 45.7 months vs 40.1 months - **Quality of Life:** Better tolerability profile - **Biomarkers:** PD-L1 not predictive in this combination ### ๐ŸŽฏ Nivolumab + Cabozantinib - **CheckMate 9ER:** Significant PFS and OS improvement - **Median PFS:** 16.6 months vs 8.3 months - **Overall Response:** 55.7% vs 27.1% - **Mechanism:** Dual immune checkpoint and angiogenesis blockade - **Tolerability:** Manageable safety profile - **All Risk Groups:** Benefit across IMDC risk categories ### โšก Lenvatinib + Pembrolizumab - **CLEAR Trial:** Superior outcomes vs sunitinib - **4-Year Data:** Long-term efficacy confirmed - **Median PFS:** 23.9 months vs 9.2 months - **Response Rate:** 71.0% vs 36.1% - **Unique Profile:** Multi-kinase inhibitor combination - **Management:** Requires dose reduction expertise ### ๐ŸŽฏ Clinical Decision Framework #### T1a (โ‰ค4cm) Management - Active surveillance for elderly/comorbid - Cryoablation for intermediate candidates - Partial nephrectomy for young/healthy - Consider histology and growth rate #### T1b-T2 (\>4cm) Management - Partial nephrectomy preferred - Radical nephrectomy for complex cases - Consider neoadjuvant therapy - Multidisciplinary team approach #### Advanced Disease - Immunotherapy combinations first-line - IMDC risk stratification - Sequence therapy based on response - Clinical trial consideration ### ๐ŸŽฏ Key Learning Points #### Size-Risk Correlation Metastatic risk increases substantially with tumor size, but histology modifies this relationship significantly. #### Personalized Management Patient factors, tumor characteristics, and preferences guide treatment selection among surgery, ablation, and surveillance. #### Immunotherapy Standard Combination immunotherapy has revolutionized advanced RCC treatment with durable survival benefits. #### Active Surveillance Safety Well-selected patients can safely delay treatment without compromising oncologic outcomes. --- [Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/kidney-cysts-masses/renal-masses/renal-cell-carcinoma.html) ยท Markdown synchronized October 3, 2026.